Cytokinetics' Aficamten Hits Primary Endpoints in Non-Obstructive HCM Trial — Cytokinetics, Incorporated

Event summary

Cytokinetics' ACACIA-HCM Phase 3 trial met both primary endpoints, showing statistically significant improvements in KCCQ-CSS and pVO2 for non-obstructive hypertrophic cardiomyopathy (nHCM) patients.
The trial enrolled 517 participants and demonstrated consistent efficacy across prespecified subgroups.
Cytokinetics plans to submit a supplemental New Drug Application to the FDA for aficamten in Q4 2026.
Aficamten was generally well-tolerated, with non-fatal adverse events leading to early discontinuation in 7% of patients on aficamten compared to 1.9% on placebo.

The big picture

Cytokinetics' success in the ACACIA-HCM trial positions aficamten as a potential first-line treatment for non-obstructive HCM, a condition with limited therapeutic options. The positive results could expand the drug's market beyond obstructive HCM, addressing a significant unmet need in cardiovascular care. The strategic move to submit a supplemental NDA in Q4 2026 underscores Cytokinetics' aggressive push to capitalize on this breakthrough.

What we're watching

Regulatory Approval: Whether the FDA will approve aficamten for non-obstructive HCM by mid-2027, given the positive Phase 3 results.
Market Expansion: How Cytokinetics will position aficamten against existing treatments for nHCM, potentially capturing a significant share of the 50% of HCM patients who are non-obstructive.
Safety Monitoring: The pace at which Cytokinetics can address and mitigate potential heart failure risks associated with aficamten, particularly in patients with lower baseline LVEF.